Pathogen Disease Sample Prep Firm NanoMR Raises $13M in Series B | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – NanoMR, a company developing diagnostics for the identification of pathogens, today announced it has raised $13 million in a Series B financing round.

The money will be used to develop commercial instruments for the clinical microbiology market, conduct clinical studies, and prepare for a product launch, the Albuquerque, NM-based firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.